#biotech

Last 24h 📊 Neutral 📈3 📉1 📊4

Last 7 Days 📊 Neutral 📈11 📉4 📊21

Last 30 Days 📊 Neutral 📈79 📉9 📊81

Release 📈 Stocks

AbbVie Shares Gain as SKYRIZI Hits Primary Endpoints in Crohn's Study

October 13, 2026 (27 days ago)

AbbVie's SKYRIZI achieves significant endoscopic remission in Phase 3 Crohn's disease trials, bolstering the company's immunology portfolio and growth outlook.

ABBV

🌍 AMERICAS Read More →

Release 📈 Stocks

Prologue Medicines Appoints Stephen Harrison as Chief Scientific Officer

October 13, 2026 (28 days ago)

Prologue Medicines bolsters its executive and board leadership, naming Stephen Harrison as CSO while welcoming new directors Jason Silvers and Adrian Rawcliffe…

Prologue Medicines Flagship Pioneering Etiome

🌍 AMERICAS Read More →

Release 📈 Stocks

Legacy Healthcare Secures FDA Breakthrough Designation for CINAINU Alopecia Drug

October 13, 2026 (28 days ago)

Legacy Healthcare gains FDA Breakthrough Therapy status for its CINAINU alopecia treatment, marking a critical regulatory advancement for the Swiss biopharmaceutical firm's…

Legacy Healthcare

🌍 EUROPE Read More →

Release 📈 Stocks

MetaVia Appoints Sarah Browne as Chief Medical Officer to Lead Drug Pipeline

October 13, 2026 (28 days ago)

MetaVia Inc. strengthens its leadership team with the appointment of Sarah Browne as Chief Medical Officer to accelerate the development of its…

MTVA

🌍 AMERICAS Read More →

Release 📈 Stocks

Intellia Therapeutics Appoints Dr. Jing Marantz as Chief Medical Officer

October 13, 2026 (28 days ago)

Intellia Therapeutics taps industry veteran Dr. Jing L. Marantz to lead its medical and regulatory strategy as the company advances its CRISPR-based…

NTLA

🌍 AMERICAS Read More →

Release 📈 Stocks

TRI Launches TRIAL.OS to Advance AI-Augmented Clinical Trial Operations

October 13, 2026 (28 days ago)

TRI introduces TRIAL.OS, a new AI-driven operating system aimed at optimizing clinical research workflows and elevating standards in risk-based quality management.

TRI

🌍 EUROPE Read More →

Release 📈 Stocks

Roche Secures Exclusive Global Rights to Rona Therapeutics' ALK7 RNAi Therapy

October 13, 2026 (28 days ago)

Roche expands its metabolic portfolio through a global licensing deal with Rona Therapeutics for an ALK7-targeting RNAi candidate, marking a significant validation…

Rona Therapeutics RO

🌍 GLOBAL Read More →

Release 📈 Stocks

Castle Biosciences TissueCypher Data Validates Barrett's Esophagus Risk

October 12, 2026 (28 days ago)

New clinical data confirms Castle Biosciences' TissueCypher platform provides critical risk stratification for Barrett's esophagus patients, potentially accelerating clinical adoption.

CSTL

🌍 AMERICAS Read More →

Release 📈 Stocks

Johnson & Johnson TREMFYA Hits 94% Remission Rate in Crohn's Disease Study

October 12, 2026 (28 days ago)

Johnson & Johnson's TREMFYA demonstrates strong efficacy in Crohn's disease trials, with 94% clinical remission and 61% endoscopic remission, bolstering the company's…

JNJ

🌍 AMERICAS Read More →

Release 📈 Stocks

Johnson & Johnson Shares Gain as TREMFYA Shows Crohn's Disease Efficacy

October 12, 2026 (28 days ago)

Johnson & Johnson's TREMFYA shows consistent perianal fistula remission in Crohn's disease patients, bolstering the company's pharmaceutical outlook.

JNJ

🌍 AMERICAS Read More →

Release 📈 Stocks

Zydus Lifesciences Reports 60.7% PBC Treatment Response in U.S. Subgroup

October 12, 2026 (29 days ago)

Zydus Lifesciences shares gain momentum as Phase 3 EPICS-III trial data reveals superior biochemical response rates for saroglitazar in U.S. patients suffering…

ZYDUSLIFE

🌍 GLOBAL Read More →

Release 📈 Stocks

Citius Pharmaceuticals CEO Leonard Mazur to Attend Two Investor Conferences

October 12, 2026 (29 days ago)

Citius Pharmaceuticals CEO Leonard Mazur is scheduled to present at the 2026 Maxim Growth Summit and the ThinkEquity Conference, facilitating direct engagement…

CTXR

🌍 AMERICAS Read More →